Other active comparator
Investigator choice oral drug
OTHER_ACTIVE_investigator_choice_oral_drug
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.20 (0.07 to 17.25) | 0.25 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.57 (0.89 to 6.85) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.03 (0.20 to 4.77) | 0.50 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.71 (0.45 to 1.13) | 0.74 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.43 (0.02 to 9.72) | 0.74 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.00 (0.43 to 2.22) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.72 (0.28 to 1.83) | 0.67 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.21 (0.01 to 4.79) | 0.80 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.61 (0.17 to 2.01) | 0.64 |